Structural Model for the Interaction of a Designed Ankyrin Repeat Protein with the Human Epidermal Growth Factor Receptor 2

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Epa, V Chandana ^a   Dolezal, Olan ^a   Doughty, Larissa ^a,c   Xiao, Xiaowen ^a   Jost, Christian ^b   Plückthun, Andreas ^b   Adams, Timothy E ^a  

^a CSIRO   (Australia)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYRIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PERTUZUMAB; TRASTUZUMAB;

ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; MACROMOLECULE; MOLECULAR DOCKING; POINT MUTATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; STATIC ELECTRICITY; STRUCTURAL BIOINFORMATICS; STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS;

ANKYRINS; CRYSTALLOGRAPHY, X-RAY; HUMANS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; SURFACE PLASMON RESONANCE;

EID: 84875098026     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059163     Document Type: Article

References (35)

1. Ross JS, Fletcher JA, (1998) The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Stem Cells 16: 413-428.
2. Yarden Y, Sliwkowski MX, (2001) Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology 2: 127-137.
3. Junttila TT, Akita RW, Parsons K, Fields C, Phillips GDL, et al. (2009) Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15: 429-440.
4. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, et al. (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756-760.
5. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, et al. (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5: 317-328.
6. Binz HK, Stumpp MT, Forrer P, Amstutz P, Plückthun A, (2003) Designing repeat proteins: Well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. Journal of Molecular Biology 332: 489-503.
7. Binz HK, Amstutz P, Kohl A, Stumpp MT, Briand C, et al. (2004) High-affinity binders selected from designed ankyrin repeat protein libraries. Nature Biotechnology 22: 575-582.
8. Boersma YL, Plückthun A, (2011) DARPins and other repeat protein scaffolds: advances in engineering and applications. Current Opinion in Biotechnology 22: 849-857.
9. Zahnd C, Wyler E, Schwenk JM, Steiner D, Lawrence MC, et al. (2007) A designed ankyrin repeat protein evolved to picomolar affinity to Her2. Journal of Molecular Biology 369: 1015-1028.
10. Theurillat JP, Dreier B, Nagy-Davidescu G, Seifert B, Behnke S, et al. (2010) Designed ankyrin repeat proteins: a novel tool for testing epidermal growth factor receptor 2 expression in breast cancer. Modern Pathology 23: 1289-1297.
11. Zahnd C, Kawe M, Stumpp MT, de Pasquale C, Tamaskovic R, et al. (2010) Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Research 70: 1595-1605.
12. Choi Y, Deane CM, (2010) FREAD revisited: Accurate loop structure prediction using a database search algorithm. Proteins: Structure, Function, and Bioinformatics 78: 1431-1440.
13. Chen R, Li L, Weng ZP, (2003) ZDOCK: An initial-stage protein-docking algorithm. Proteins-Structure Function and Genetics 52: 80-87.
14. Lensink MF, Mendez R, Wodak SJ, (2007) Docking and scoring protein complexes: CAPRI 3rd edition. Proteins-Structure Function and Bioinformatics 69: 704-718.
15. Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, et al. (2009) Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323: 1610-1614.
16. Sennhauser G, Grütter MG, (2008) Chaperone-assisted crystallography with DARPins. Structure 16: 1443-1453.
17. Mendez R, Leplae R, Lensink MF, Wodak SJ, (2005) Assessment of CAPRI predictions in rounds 3-5 shows progress in docking procedures. Proteins-Structure Function and Bioinformatics 60: 150-169.
18. Steiner D, Forrer P, Plückthun A, (2008) Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display. Journal of Molecular Biology 382: 1211-1227.
19. Pierce B, Weng ZP, (2007) ZRANK: Reranking protein docking predictions with an optimized energy function. Proteins-Structure Function and Bioinformatics 67: 1078-1086.
20. Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, et al. (2005) The FoldX web server: an online force field. Nucleic Acids Research 33: W382-W388.
21. Lawrence MC, Colman PM, (1993) Shape complementarity at protein-protein interfaces. Journal of Molecular Biology 234: 946-950.
22. Moont G, Gabb HA, Sternberg MJE, (1999) Use of pair potentials across protein interfaces in screening predicted docked complexes. Proteins-Structure Function and Genetics 35: 364-373.
23. McCoy AJ, Epa VC, Colman PM, (1997) Electrostatic complementarity at protein/protein interfaces. Journal of Molecular Biology 268: 570-584.
24. Wallace AC, Laskowski RA, Thornton JM, (1995) Ligplot- a program to generate schematic diagrams of protein ligand interactions. Protein Engineering 8: 127-134.
25. Jones S, Thornton JM, (1996) Principles of protein-protein interactions. Proceedings of the National Academy of Sciences of the United States of America 93: 13-20.
26. Kruger DM, Gohlke H, (2010) DrugScore(PPI) webserver: fast and accurate in silico alanine scanning for scoring protein-protein interactions. Nucleic Acids Research 38: W480-W486.
27. Wiederstein M, Sippl MJ, (2005) Protein sequence randomization: Efficient estimation of protein stability using knowledge-based potentials. Journal of Molecular Biology 345: 1199-1212.
28. Northrup SH, Erickson HP, (1992) Kinetics of protein protein association explained by Brownian dynamics computer-simulation. Proceedings of the National Academy of Sciences of the United States of America 89: 3338-3342.
29. Laskowski RA, (2009) PDBsum new things. Nucleic Acids Research 37: D355-D359.
30. Eswar N, Webb B, Marti-Renom MA, Madhusudhan MS, Eramian D, et al. (2006) Comparative protein structure modeling using Modeller. Current Protocols in Bioinformatics/editoral board, Andreas D Baxevaniset al. Chapter 5: Unit 5.6.
31. Adams TE, Koziolek EJ, Hoyne PH, Bentley JD, Lu L, et al. (2009) A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo. Growth Factors 27: 141-154.
32. Durocher Y, Perret S, Kamen A (2002) High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Research 30.
33. Garrett TPJ, McKern NM, Lou MZ, Elleman TC, Adams TE, et al. (2003) The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Molecular Cell 11: 495-505.
34. Bravman T, Bronner V, Lavie K, Notcovich A, Papalia GA, et al. (2006) Exploring "one-shot" kinetics and small molecule analysis using the ProteOn XPR36 array biosensor. Analytical Biochemistry 358: 281-288.
35. Nahshol O, Bronner V, Notcovich A, Rubrecht L, Laune D, et al. (2008) Parallel kinetic analysis and affinity determination of hundreds of monoclonal antibodies using the ProteOn XPR36. Analytical Biochemistry 383: 52-60.